Clinical Trial Update: Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating pembrolizumab in combination with binimetinib in locally advanced or metastatic triple-negative breast cancer has completed;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• MEKTOVI (BINIMETINIB)

Snippet

Sponsor: Mayo Clinic | Conditions: Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-08-20